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Introduction: Image-guided interstitial (IRT) brachytherapy (BRT)
is an effective treatment option as part of a multimodal approach to
the treatment of isolated lung tumors. In this study, we report our
results of computed tomography-guided IRT high-dose-rate (HDR)
BRT in the local treatment of inoperable primary and secondary
intrathoracic malignancies.
Methods: Between 1997 and 2007, 55 patients underwent a total of
68 interventional procedures for a total of 60 lung lesions. The
median tumor volume was 160 cm3 (range, 24–583 cm3). Thirty-
seven patients were men and 18 were women, with a median age of
64 years (range, 31–93 years). The IRT-HDR-BRT delivered a
median dose of 25.0 Gy (range, 10.0–32.0 Gy) in twice-daily
fractions of 4.0 to 15.0 Gy in 27 patients and 10.0 Gy (range,
7.0–32.0 Gy) in once-daily fractions of 4.0 to 20.0 Gy in 28 patients.
Results: The median follow-up was 14 months (range, 1–49
months). The overall survival rate was 63% at 1 year, 26% at 2
years, and 7% at 3 years. The local control rate for metastatic tumors
was 93%, 82%, and 82% and for primary intrathoracic cancers 86%,
79%, and 73% at 1, 2, and 3 years, respectively. Pneumothoraces
occurred in 11.7% of interventional procedures, necessitating post-
procedural drainage in one (1.8%) patient.
Conclusions: In patients with inoperable intrathoracic malignancies,
computed tomography-guided IRT-HDR-BRT is a safe and effec-
tive alternative to other locally ablative techniques.
Key Words: CT-guided interstitial brachytherapy, Intrathoracic
malignancies, Local ablation.
(J Thorac Oncol. 2011;6: 545–552)
For patients with localized primary lung cancer or oligo-metastatic pulmonary disease, surgical resection is widely
recognized as the only potentially curative treatment and has
shown clear evidence to improve survival.1–4 Nevertheless, a
considerable proportion of patients are not considered candi-
dates for lung surgery for medical and technical reasons. In
other cases, patients may refuse surgical intervention. For
these patients, minimally invasive therapies have attained
increasing utilization, mostly in the form of hyperthermic
techniques such as radiofrequency ablation (RFA) and laser-
induced thermotherapy (LITT).5–11
Computed tomography (CT)-guided interstitial (IRT)
high-dose-rate (HDR) brachytherapy (BRT) enables the
highly conformal administration of very large radiation doses
to a circumscribed volume. This modality has proven effica-
cious in the treatment of both primary and secondary cancers
at various sites.12–21 CT-guided IRT-BRT seems to be an
attractive alternative to other local interventional treatment
techniques because it ensures not only accurate image guid-
ance but also precisely predictable energy deposition. Nev-
ertheless, a paucity of outcome data exists regarding the
treatment of intrathoracic tumors with image-guided IRT-
HDR-BRT.13,22 The aim of this review is to report our clinical
experience with CT-guided IRT-HDR-BRT in the local treat-
ment of inoperable intrathoracic malignancies.
PATIENTS AND METHODS
Patients
Between January 1997 and December 2007, 55 patients
were treated with CT-guided IRT-HDR-BRT for primary or
secondary intrathoracic tumors. All patients included were
not surgical candidates secondary to excessive medical co-
morbidities, previous lung surgery, or refusal to undergo
surgical procedures.
The study population included 37 men and 18 women,
with a median age of 64 years (range, 31–93 years). Patients
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with primary intrathoracic cancers (non-small cell lung can-
cer [NSCLC] and malignant pleural mesothelioma [MPM],
n  41, 74.5%) and patients with pulmonary metastases
(n  14, 25.5%) were treated. Patients with primary
cancers had initial histologic confirmation of malignancy
in all cases. Among patients with pulmonary metastases,
biopsy confirmation was performed in eight patients and
omitted in six cases.
All patients with metastatic disease had progressive
metachronous lesions with the underlying primary malig-
nancy treated at the time of BRT. In patients with primary
cancers, treatment was performed for progressive or local
recurrent disease. Among those, 13 (31.7%) patients had
undergone thoracic surgery and 29 (70.7%) had received
external beam radiotherapy (EBRT). Thirty-one patients
(75.6%) had undergone chemotherapy (ChT) as a part of their
primary treatment regimen.
The lesions treated by BRT had a median volume of
160 cm3 (range, 24–583 cm3) with a mean value of 211 cm3.
Pretreatment evaluation was based on contrast-enhanced
chest CT in all patients. In four (7.2%) patients treated since
2006, fluorodeoxyglucose (FDG) positron emission tomogra-
phy (PET)/CT was also performed. Invasive procedures were
not part of staging modalities. Lesion-specific treatment be-
fore BRT consisted of thoracic EBRT with median 36.0 Gy
(range, 20–90 Gy) in 36 (65.4%) patients and multiple cycles
of different ChT regimes in 49 (89.0%) patients. No patient
received ChT or additive EBRT in conjunction with BRT,
and no patient received further EBRT to the implant sites
following BRT. The median Karnofsky Performance Score
(KPS) at the time of BRT was 80 (range, 60–100). Details of
the treated lesions are presented in Table 1.
Brachytherapy
Our technique of CT-guided IRT-BRT has been described
in detail elsewhere.12 In short, catheter placement was performed
using CT-guidance (Somatom Plus 4, Siemens, Erlangen, Ger-
many). Round-tip plastic catheters of 6F diameter and 200 mm
length (OncoSmart ProGuide Round Needle-Nucletron,
Veenendaal, The Netherlands) were implanted using a rigid
tungsten alloy obturator of the same length and diameter (Onco-
Smart ProGuide Obturator-Nucletron, Veenendaal, The Neth-
erlands). This allowed for maintenance of catheter integrity
and stability during insertion. After removal of the obturator,
positional control was obtained by generating CT images
with the catheter in situ. Thus, maximum insertion depth,
direction, and position of the implanted catheters were estimated
by interactive CT scanning. Number, geometrical alignment,
and distance between the catheters were dependent on the size,
shape, and location of the tumor. For spherical lesions up to 3 cm
in diameter, one central catheter was usually utilized. In larger or
nonspherical tumors, multiple catheters were used. For lesions
adherent to the chest wall, this allowed, in principle, the insertion
of more applicators than those located centrally. Although a
parallel catheter alignment without course intersections inside
the implanted volume is ideal, anatomy-oriented treatment plan-
ning allowed for individual catheter configurations. The goal
was to have the largest distance between catheters to be not more
than 3 cm.
After catheter placement, a contrast-enhanced (iodide
contrast media: Imeron 300, Bracco Imaging, Konstanz, Ger-
many) spiral CT (slice thickness, 3.0 mm; table movement,
3.0 mm) of the treatment area was acquired for three-dimen-
sional (3D) treatment planning.23 Tumor demarcation with
corresponding target volume (PTV) delineation was per-
formed using ProSoma virtual simulation software (Medcom
GmbH, Darmstadt, Germany). For 3D-dose optimization,23
performed using Plato BPS (Nucletron, Veenendaal, The
Netherlands), active source dwell positions were selected
along the catheters to ensure placement inside the PTV and to
assure a location at 5.0 to 10.0 mm below the PTV surface.
The dose distribution was normalized relative to the calcu-
lated mean dose value on the PTV surface with the reference
dose specified as the 100% value (Figures 1A, B).
Treatment schemes and dose restrictions were individ-
ually determined depending on the tumor location to spare
adjacent risk structures. Although treatment plan optimiza-
tion was carried out with respect to conformity, maximum
single spinal cord doses 8 Gy with maximum total spinal
cord doses 20 Gy were our institutional constraints in
radiation-naive patients. For preirradiated sites, treatment
schemes and restrictions were determined after careful in-
spection of the dose-volume histogram (DVH) to ensure
cumulative spinal cord dose 60 Gy. For preservation of
lung function, 5 Gy to 70% of the ipsilateral lung served
as the specified dose limit. Treatments were performed over
consecutive days with an interfractional interval of at least 6
TABLE 1. Details of the Lesions Treated With Interstitial Brachytherapy
No. of
Patients (%)
No. of
Lesions (%)
No. of
Interventions (%)
Tumor entity
Colorectal carcinoma 2/55 (3.6%) 2/60 (3.3%) 2/68 (2.9%)
Soft-tissue sarcoma 7/55 (12.7%) 7/60 (11.6%) 8/68 (11.7%)
Hypernephroid renal carcinoma 2/55 (3.6%) 2/60 (3.3%) 2/68 (2.9%)
Metastases of NSCLC 2/55 (3.6%) 6/60 (10.0%) 7/68 (10.2%)
Primary NSCLC 36/55 (65.4%) 36/60 (60.0%) 40/68 (58.8%)
Primary malignant pleural mesothelioma 5/55 (9.0%) 6/60 (10.0%) 8/68 (11.7%)
Unknown primary 1/55 (1.8%) 1/60 (1.6%) 1/68 (1.4%)
NSCLC, non-small cell lung cancer.
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hours. Catheters were removed immediately after the last frac-
tion. All irradiations were performed using an Iridium-192
(192Ir) HDR-afterloading system (microSelectron-HDR, Nucle-
tron, Veenendaal, The Netherlands) with an apparent initial
source activity of approximately 370 GBq.
Assessment and Statistical Analysis
Treatment assessment was based on tumor volume
response. This method was deemed to be more accurate than
a two-dimensional (2D) diameter description24 and defined
according to modified World Health Organization response
criteria for solid tumors25 at 8 to 12 weeks after BRT. Any
decrease of more than 30% in tumor volume was interpreted
as partial response (PR), any increase of more than 20% as
progressive disease (PD), and no measurable lesions (except
CT findings of residual scar tissue with no contrast enhance-
ment) were considered as complete response (CR). Stable
disease (SD) met neither PR nor PD criteria. Tumor volume
was measured using the IPS module of PLATO BPS (Nucle-
tron, Veenendaal, The Netherlands) and the virtual simulation
software ProSoma (MedCom GmbH, Darmstadt, Germany)
based on contrast-enhanced CT scans. After the initial treat-
ment evaluation, further follow-up was complemented by
contrast-enhanced CT at 8- to 12-week intervals thereafter.
Not all patients returned for every scheduled examination;
however, data collection allowed external CT reading or
information acquisition from referring physicians.
Statistical analyses were performed using the Kaplan-
Meier method26 and comparisons made using the log-rank
test.27 The time point of treatment initiation was the date of
the first BRT procedure. The end point of interest for overall
survival (OS) was death from any cause. The end point of
interest for local control (LC) was local failure after SD, PR,
or CR. In the absence of pathologic confirmation of malignancy,
local failure was defined as tumor growth or regrowth per CT
scan compared with the previous CT scan. As some patients had
more than one BRT procedure, survival analysis was performed
among all patients with respect to each patient’s first BRT
procedure, whereas complications were analyzed with respect to
all performed interventions. For matching purposes of the dif-
ferent treatment schemes included in our study, the EQD2 was
calculated. EQD2 is the equivalent dose as if the treatment was
given with a 2.0 Gy conventional fractionation based on the
following formula:
EQD2 nd
1 d
/

1 2
/

where /  the ratio of the tissue, n  the number of BRT
fractions, and d  the dose per BRT fraction. For our
calculations, the / ratio was taken to be 10 Gy.28
RESULTS
Radiotherapy Details
A total of 68 interventional procedures were performed
on 55 patients for the treatment of 60 tumors (Table 1).
Eleven (20.0%) patients received multiple implants. Of those,
seven patients received a second or third implant for local
disease progression, four patients a second implant for new
intrapulmonal metastases, and one patient a second implant
for a new contralateral MPM. All patients received treatment
for only one single lesion per interventional session with no
patient having multiple simultaneous sites implanted. All
implants were performed under local anesthesia with mepi-
FIGURE 1. A 74-year-old man with adenocarcinoma of the right-sided superior sulcus. The radiation-naive patient rejected
surgery and radiochemotherapy and was treated by sole interstitial high-dose-rate brachytherapy receiving four fractions of
8.0 Gy over 2 consecutive days to a total physical dose of 32.0 Gy. A, Image of the interstitial implant after completion of the
computed tomography (CT)-guided catheter insertion procedure. The six flexible catheters are fixed at the entrance points on
the skin surface by surgical suture. B, Axial CT image with superimposed two-dimensional (2D)-isodose distribution after CT-
based three-dimensional (3D)-treatment planning for a plane lying centrally to the target extension. The color gradation rep-
resents red  300% isodose  24.0 Gy, pink  200% isodose  16.0 Gy, yellow  150% isodose  12.0 Gy, orange 
100% isodose  8.0 Gy, and light green  60% isodose  4.8 Gy. The tumor volume is red delineated (PTV) with the six
implanted catheters identifiable as dark dots inside it. The central tumor volume is covered at least by the 300% isodose and
receives total doses of at least 96.0 Gy within 48 hours. The spinal cord is only marginally covered by the 60% isodose and
receives a fractionated total dose far below 20.0 Gy.
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vacaine hydrochloride and conscious sedation with midazo-
lam plus pethidine intravenously.
With respect to each patient’s first BRT procedure, 27
(49.0%) patients received twice-daily fractions of median 6.0 Gy
(range, 4.0–15.0 Gy) and 28 (50.9%) patients once-daily frac-
tions of median 8.0 Gy (range, 4.0–20.0 Gy) to a median total
HDR dose of 20.0 Gy (range, 7.0–32.0 Gy). When expressed as
EQD2, the median dose to the implanted sites was 29.8 Gy.
In addition to the prescribed reference dose, the D90, as
determined by the DVH of the PTV, is reported. Similarly,
dose heterogeneity was specified by V100, V150, and V200.
Median values for our series were V100  88.5% (range, 63.0–
98.0%), V150  58.0% (range, 42.0–80.0%), and V200 
40.0% (range, 27.0–63.0%). The median achieved D90 value
was equivalent to 95.0% (range, 44.0–127.0%) of the pre-
scribed reference dose.
Response, Survival, and Disease Control
The overall response (defined as the sum of CR and PR)
at median 11 weeks after BRT was 67.2% (37 patients) with 10
(18.1%) patients exhibiting CR and 27 (49.0%) PR. Of the
remaining 18 patients, 15 (27.2%) had SD, and three (5.4%) had
PD. Metabolic responses by FDG-PET/CT were available in all
four patients with pretreatment PET-based evaluation but were
not considered in the scoring of responses. In all cases, there was
complete resolution of metabolic activity with the patients ex-
hibiting partial radiological response.
The median OS was 15.5 months with an OS rate of 63%
at 1 year, 26% at 2 years, and 7% at 3 years (Figure 2). The
estimated overall LC was 88% at 1 year, 81% at 2 years, and
75% at 3 years. The LC rate for metastatic tumors was 93%,
82%, and 82% and for primary intrathoracic cancers 86%, 79%,
and 73% at 1, 2 and 3 years, respectively (Figure 3).
Twenty-three of 41 (56.0%) patients with primary in-
trathoracic tumors experienced extrapulmonary disease progres-
sion after a median of 5.4 months (range, 1–35 months), and 13
(31.7%) died as a consequence. Of the 14 patients treated for
secondary pulmonary malignancies, eight (57.1%) patients de-
veloped extrapulmonary disease progression after a median of
11.5 months (range, 7–21 months). Six patients (42.8%) died as
a consequence. Intrapulmonary disease progression was the
cause of death in four (7.2%) patients. In addition, there were 31
(56.3%) deaths of intercurrent causes (myocardial infarction,
pulmonary embolism, cerebrovascular bleeding, hemorrhage of
the digestive tract, septic shock, alcohol-induced hepatic failure,
general deterioration, and suicide). Overall follow-up ranged
from 5 weeks to 49 months (median, 14 months), and 35 patients
reached the 1-year, 12 patients the 2-year, and three patients the
3-year follow-up. One (1.8%) patient was alive at the time of
reporting (i.e., March 2010).
Prognostic Factors
The variables considered for analysis were median
EQD2 (29.8 Gy versus 29.8 Gy), median pretreatment
tumor volume (160 cm3 versus 160 cm3), and relative
tumor volume reduction ([Vbefore BRT Vafter BRT]/Vbefore BRT,
85% versus 85%). In univariate analysis, we failed to
show a statistically significant correlation between survival
and tumor volume reduction, pretreatment tumor volume, or
applied treatment dose.
With respect to LC failure, we could confirm tumor
volume reduction to have an impact on local tumor control
with a rate of 84% at 12 months after volume reduction less
than 85% versus 100% for volume reduction 85% (p 
0.048). In contrast, we failed to show a statistically significant
correlation between pretreatment tumor volume or applied
treatment dose and achieved LC rate.
In our series, complete tumor remissions were accom-
plished only in tumors110 cm3 (Figure 4). Taking the limit
volume of 110 cm3 as a threshold, we found that LC at 12
months was 84% for lesions less than 110 cm3 versus 88% for
lesions 110 cm3 (p  0.397). This difference was not
statistically significant. Additionally, there was no statisti-
cally significant correlation between response rates and ap-
plied treatment dose.
Complications
Sixteen (23.5%) acute adverse events occurred in 68
interventional procedures with no procedure-related lethal
FIGURE 2. Kaplan-Meier curve for overall survival after in-
terstitial brachytherapy.
FIGURE 3. Kaplan-Meier curves for local control after inter-
stitial brachytherapy.
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events and no late toxicities (Table 2). Eight (11.7%) of the
complications were pneumothoraces, all of which developed
after catheter removal. Seven were self-limiting and associated
with the treatment of peripheral tumors. One required chest-tube
drainage and developed after treatment of a centrally located
tumor. One case of acute upper extremity edema and one case of
acute upper extremity dysesthesia were associated with proce-
dures in the ipsilateral superior sulcus. Both events had minor
sequelae and resolved completely with conservative care. One
case of major pneumothorax and one case of acute-onset pneu-
monia required hospitalization for 15 and 21 days, respectively.
There was no discernible statistical correlation between compli-
cation rates and pretreatment tumor volume or applied treatment
dose. The median length of hospital stay was 5 days (range,
3–21 days).
DISCUSSION
Surgical resection is widely considered the preferred
treatment for localized primary lung cancer and oligometastatic
pulmonary disease.1–4 However, in practice, there is a subgroup
of patients who are not candidates for this approach.22 Treatment
options for these patients include ChT29,30 with or without
EBRT.31–34 Recently, improvements in survival have been
achieved with the implementation of targeted therapies35,36
using a multimodal approach. Nevertheless, outcomes asso-
ciated with noninvasive modalities themselves remain dis-
mal.35–37 In this challenging clinical setting, minimally inva-
sive approaches have drawn increasing attention, especially
hyperthermal techniques such as RFA and LITT.5–8,10,11
Unfortunately, high-complication rates have been reported
with these techniques.5–8,10,38
CT-guided IRT-HDR-BRT has proven efficacious in the
treatment of various primary and secondary malignancies.12–21
Compared with hyperthermal techniques such as RFA and
LITT, factors such as tissue inhomogeneity, thermal conductiv-
ity, and tumor perfusion do not prohibit complete ablation.5–7,10
Moreover, the maximum lesion size for successful radioablation
has not been determined. There is a paucity of data on the use
of image-guided IRT-HDR-BRT in the treatment of intratho-
racic tumors not amenable to surgery. Imamura et al.13 treated
12 patients with inoperable primary lung cancer by CT-
guided 192Ir-HDR-BRT of 20 to 25 Gy. The mean irradiated
tumor volume was 37.0 ml, and the achieved response rate
was 58.3% with 25% of patients showing CR, 33% PR, and
42% SD. No patient experienced severe complications. Peters
et al.22 treated 30 patients with 83 primary or secondary
pulmonary malignancies by single-fraction CT-guided 192Ir-
HDR-BRT in 50 therapy sessions. The prescribed dose of 20
Gy was referred to a mean tumor diameter of 25.0 mm, and
the overall response rate was 36% with 0% of evaluated
lesions exhibiting CR, 36% showing PR, and 42% SD. The
LC rate was 91% at 12 months and 86% at 20 months. Six
patients (12% of interventions) developed marginal pneumo-
thoraces and one patient (1% of interventions) a major pneu-
mothorax. Our series of 55 patients refers to a median tumor
volume of 160 cm3 with a complete and overall response rate
to BRT of 18% and 67%, respectively. The overall local
tumor control was 88% at 1 year, 81% at 2 years, and 75% at
3 years with corresponding rates for the subgroup of meta-
static tumors of 93%, 82%, and 82%, respectively. These data
are similar to those of other HDR-BRT series13,22 and com-
pare favorably with recently published results of RFA9 and
LITT.11
The rate of complications in our series was independent
of tumor volume and lower than that reported for hyperther-
mal techniques.5–8,10,11 Yasui et al.6 reported minor pneumo-
thoraces in 35% of sessions, pneumothoraces necessitating a
chest tube in 7% of sessions, and an overall complication rate
of 76% among 35 patients receiving 54 RFA treatments for
99 thoracic tumors with a median diameter of 19.5 mm. Vogl
et al.10 treated 30 patients with primary lung cancers or
pulmonary metastases using LITT. None of the evaluated
lesions had a diameter more than 30.0 mm, and the rate of
pneumothoraces was 9.8%. Rosenberg et al.11 reported on 64
patients treated by LITT for pulmonary metastases with a
median size of 20.0 mm. Pneumothoraces necessitating drain-
age developed in 5% of treatments. In our series, we had a
1.4% rate of major pneumothoraces and 10.2% rate of minor
pneumothoraces, rates that parallel the results of Peters et al.22
FIGURE 4. Relationship of tumor volumes before and after
interstitial brachytherapy for 55 patients with respect to
each patient’s first brachytherapy (BRT) procedure.
TABLE 2. Complications of Interstitial Brachytherapy
Complication
(Type)
No. of
Interventions (%) Extent
Pneumothorax
(acute)
7/68 (10.2%) Minor (self-resolving)
1/68 (1.4%) Major (requiring chest tube)
Cough (acute) 5/68 (7.3%) Minor (conservatively treated)
Pneumonia (acute) 1/68 (1.4%) Major (requiring IV antibiotics)
Upper extremity
edema (acute)
1/68 (1.4%) Minor (conservatively treated)
Upper extremity
dysesthesia (acute)
1/68 (1.4%) Minor (conservatively treated)
IV, intravenous.
Journal of Thoracic Oncology • Volume 6, Number 3, March 2011 CT-Guided BRT for Intrathoracic Malignancies
Copyright © 2011 by the International Association for the Study of Lung Cancer 549
Compared with hyperthermal ablation data, the LC
achieved in our series was independent of tumor size. Taking
our median tumor volume of 160 cm3 as a threshold, we
found that LC at 12 months was 93% for lesions less than 160
cm3 versus 96% for lesions 160 cm3 (p  0.236). Rosen-
berg et al.11 reported a tumor progression rate of 33% for
tumors larger than 40.0 mm and a tumor progression rate of
19% for tumors smaller than 15.0 mm. The median progres-
sion-free intervals were 1.9 months and 5.0 months, respec-
tively. As a matter of principle, no limitations exist regarding
the target volume for IRT-HDR-BRT. The successful appli-
cation of thermal techniques, on the other hand, correlates
with the size of the lesion undergoing treatment. Jin et al.8
evaluated 21 patients with primary and secondary lung can-
cers treated by RFA, showing that the mean diameter of
completely ablated lesions was 28.0 mm, whereas for par-
tially ablated tumors, it amounted 49.0 mm.
With respect to the applied treatment dose, Willner et
al.39 were able to show a significant correlation between
radiation dose and local tumor control. The authors found a
clearly improved effect with EBRT doses 70 Gy in the
primary treatment of NSCLC. Furthermore, Martel et al.40
estimated that normally fractionated doses of more than 84
Gy are needed to achieve a 50% probability of local tumor
control in the treatment of NSCLC. Our data suggest that the
delivered treatment dose has no significant impact on LC,
neither for the subgroup of metastatic lesions nor in the
treatment of primary cancers.
Similar to Peters et al.,22 we experienced lesions which
exhibited a PR to treatment with no further changes over a
long follow-up period. Nevertheless, biopsies were not rou-
tinely performed in association with follow-up imaging. As
almost half of our patients (n  27, 49.0%) received further
ChT for systemic disease progression, it is difficult to ascer-
tain which findings were attributable to the BRT per se. On
the other hand, 89.0% of our patients were heavily pretreated
with ChT, and several had received prior thoracic EBRT. It is
questionable whether additional ChT would have had an
impact in a microenvironment of previous systemic treatment
failure and after repeat irradiation with HDR-BRT. Mean-
while, we had complete tumor volume remissions (Figures
5A–C) in 18.1% of patients with lesions 110 cm3. Never-
theless, there was no statistically significant difference in
local tumor control for lesions less than 110 cm3 versus110
cm3 (p  0.397). This finding could support the assumption
by Peters et al.22 that in IRT-HDR-BRT of the lung, generally
accepted response criteria may not always adequately de-
scribe the actual clinical response.
Despite encouraging LC data, long-term survival was
poor in our series with an OS rate of only 7% at 3 years.
Nevertheless, more than half of our patients (56.3%) did not
die of lung cancer but of intercurrent causes. It should be
taken into consideration that treatment selection bias may
play a role in survival. Greater than 90% of our patients were
judged medically inoperable with multiple medical comor-
bidities. Given that most of patients were also extensively
pretreated for local disease progression before BRT, the
FIGURE 5. A 77-year-old man with squamous cell carci-
noma of the left-sided superior sulcus. The patient suffered
from chronic obstructive pulmonary disease, chronic renal
insufficiency, and chronic cardiac insufficiency as coexisting
morbidities and was medically not amenable to lung sur-
gery. He rejected radiochemotherapy and was treated by
sole interstitial high-dose-rate brachytherapy receiving four
fractions of 8.0 Gy over 2 consecutive days to a total physi-
cal dose of 32.0 Gy. A, Axial computed tomography (CT)-
image obtained before the onset of treatment showing a
massive lesion in the apical part of the left lung lobe. The
single implanted catheter is marked with a red circle in the
central part of the red delineated tumor volume (Target).
B, Two-dimensional (2D)-isodose distribution after three-
dimensional (3D)-treatment planning for a plane lying cen-
trally to the target extension. The color gradation represents
the same isodose values as in Figure 1B. C, Axial CT image
obtained at 13 months after brachytherapy showing no tu-
mor regrowth.
Tselis et al. Journal of Thoracic Oncology • Volume 6, Number 3, March 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer550
high-rate intercurrent deaths in our current series cannot be
considered unanticipated.
As the tolerance of pulmonary parenchymal tissue de-
creases with increased irradiated lung volumes,41 conven-
tional radiation techniques rarely achieve durable control
without excessive morbidity. Stereotactic body radiation ther-
apy (SBRT) is a sophisticated percutaneous technique that
has the potential to improve the therapeutic ratio by reducing
treatment volumes, while escalating treatment doses.42–44
Both robotic delivery devices (CyberKnife, Accuray, Sunny-
vale, CA) and gantry-operated linear accelerators have been
evaluated in the stereotactic treatment of primary and meta-
static lung cancers, either for severe hypofractionated radio-
therapy (HSRT) or as single-fraction radioablation (SFRA).
For HSRT, dose fractionations from 33 Gy/6 up to 60 Gy/3
fractions have been reported with LC rates ranging from
73.0% crude to 97.7% at 2 years.45–54 Similarly, a consider-
able variation in dose schemes has been described for SFRA
with doses from 15 to 30 Gy yielding 2-year control rates
from 48 to 91%.55–60 However, the predominantly favorable
results reported for SBRT suggest a beneficial prognostic
impact of smaller tumor size (5 cm) on local tumor control.
In the reported HSRT studies, the median tumor size for LC
more than 85% at 2 years ranged from 4.2 to 43.9 ml and for
SFRA from 6.0 to 40.0 ml. In our series, the median tumor
volume was 160 cm3 with an overall LC rate of 81% at 2
years. Another factor which potentially limits SBRT is respi-
ratory tumor motion.61 Although different methods have been
exploited to decrease the volume irradiated (motion-encom-
passing methods, respiratory-gated techniques, breath-hold
techniques, forced shallow-breathing methods, and respira-
tion-synchronized techniques), some of them are difficult to
tolerate, and not all patients are suitable for every technique.
As such, breathing mobility remains a factor for inaccuracy,
and the displacement of tumors due to respiratory motion can
be considerable with significant individual variability.62 Nev-
ertheless, SBRT is a noninvasive technique with proven
efficacy in the treatment of small- to medium-sized tumors
and is becoming more widely utilized on various treatment
platforms. In this context, CT-guided IRT-HDR-BRT is a
meaningful additional modality that can be implemented for
the treatment of larger lesions or when stereotactic radiation
delivery systems are not available. In this study, the inher-
ently nonhomogeneous dose distribution in BRT parallels the
intrinsic capability of SBRT to perform simultaneous intra-
tumoral dose boosting.63 Compared with SBRT, however,
BRT provides a higher degree of intratumoral dose hetero-
geneity with no upper dose limits and a sharper dose fall-off
gradient outside the target volume. The latter is of particular
importance as it facilitates the application of very high doses
to central tumor areas which might experience increased
radioresistance due to hypoxic tumor microenviroment.63
The treatment schemes in our series were risk adapted
based on individual clinical features. Different histologies
and symptomatologies, and tumor locations with proximity to
critical structures were determining factors for the heteroge-
neous total doses and the nonuniform number and size of
treatment fractions. Although the appropriate HDR scheme
for local disease control has not been yet defined, our expe-
rience shows that a fractionated approach over consecutive
days is safe and feasible. The current procedure in our
department encompasses the application of 8.0 Gy twice-
daily fractions up to 32.0 Gy independent of tumor volume or
location. However, lesion size and position are decisive for
the number and alignment of the catheters, associated patient
discomfort, and treatment-related risks. All these factors can,
in consideration of dose constraints, necessitate the adminis-
tration of differing treatment schemes.
The limitations of our study are the retrospective design
and results from a relatively small population with metastases
and primary cancers. Despite these shortcomings, our data
show promising control rates and support the implementation
of CT-guided IRT-HDR-BRT in the local treatment of pri-
mary and secondary intrathoracic malignancies in nonsurgi-
cal candidates.
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